Form 4: Verona Pharma CEO David Zaccardelli Reports Share Transaction
SEC Form 4 Filing
David Zaccardelli, CEO of Verona Pharma plc, reports a transaction involving the withholding of ordinary shares to cover tax obligations related to vested restricted share units.
Summary
- On August 1, 2024, Verona Pharma plc CEO David Zaccardelli reported a transaction on SEC Form 4.
- The transaction involved the withholding of 88,544 ordinary shares to satisfy tax obligations related to the vesting of previously reported Restricted Share Units.
- The price per share for the transaction was $2.8325.
- Following the transaction, Zaccardelli beneficially owns 15,765,504 ordinary shares.
- Zaccardelli has granted power of attorney to Andrew Fisher and Mark Hahn to act on his behalf for SEC filings.
Sentiment
Score: 7
Explanation: The document reflects a neutral event (tax withholding) related to executive compensation, which is a normal part of company operations. The sentiment is therefore moderately positive as it indicates standard corporate governance and compensation practices.
Industry Context
This filing is a routine disclosure related to executive compensation and share ownership, common for publicly traded companies. It provides transparency regarding the CEO's holdings and transactions in the company's stock.
Comparison to Industry Standards
- Executive compensation practices, including the use of restricted share units and the subsequent withholding of shares for tax obligations, are standard across publicly traded companies.
- The reporting requirements under Section 16 of the Securities Exchange Act are consistently applied to ensure transparency in insider trading and executive compensation.
- Companies like GlaxoSmithKline, AstraZeneca, and Novartis also regularly disclose similar transactions by their executives.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it relates to the CEO's personal tax obligations.
- Employees may be indirectly affected as executive compensation practices can influence overall company morale and performance.
Key Dates
| Date | Description |
|---|---|
| 2024/05/22 | Date of execution for Power of Attorney. |
| 2024/07/31 | Date used to calculate the price of the Issuer's ADSs on the Nasdaq Stock Market LLC. |
| 2024/08/01 | Date of the transaction involving the withholding of ordinary shares. |
| 2024/08/05 | Date of signature for the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.